medigraphic.com
Asociación Mexicana de Gastroenterología

2007, Number 3

<< Back Next >>

Rev Gastroenterol Mex 2007; 72 (3)

Treatment of serious CUC and conduct of follow-up to evaluate the risk of cancer

Bosques-Padilla F

Language: Spanish
References: 105
Page: 309-319
PDF size: 77.00 Kb.


Text Extraction

No abstract


REFERENCES

  1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041-5.

  2. Cohen LJ, Strong AS, Hyman HN, Buie WD, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2005; 48(11): 1997-2009.

  3. Hanauer S. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.

  4. Tremaine WJ, Sandborn WJ, Loftus EV, et al. A prospective cohort study of practice guidelines for inflammatory bowel disease. Am J Gastroenterol 2001: 2401-6.

  5. Truelove SC, Jewell D. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.

  6. Truelove SC, Willoughby CP, Lee G, et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 1978; 2: 1086-8.

  7. Jarnerot G, Rolny P, Saulbergh-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.

  8. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in ulcerative colitis. Gut 1986; 27: 1210-2.

  9. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin vs hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983; 85: 351-7.

  10. Kaplan HP, Portnoy B, Binder HJ, et al. A controlled evaluation of intravenous adrenocorticotropic hormone and hydrocortisone in the treatment of acute colitis. Gastroenterology 1975; 69: 91-5.

  11. Powell-Tuck J, Bucknell NA, Lennard-Jones JE. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 1977; 12: 971-5.

  12. Rosenberg W, Ireland A, Jewell D. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 1990; 12: 40-1.

  13. Dickinson RJ, O’Connor HJ, Pinder I, et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-4.

  14. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute severe ulcerative colitis. Scand J Gastroenterol 2001; 36: 971-4.

  15. Dickinson RJ, Ashton MG, Axon ATR, et al. Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology 1980; 79: 1199-2004.

  16. McIntyre DB, Powell-Tuck J, Wood SR. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27: 481-5.

  17. Roediger WE. The starved colon-diminished mucosal nutrition, diminished absorption and colitis. Dis Colon Rectum 1990; 33: 858-62.

  18. Koretz RL, Lipman TO, Klein S. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121: 970-1001.

  19. Kornbluth A, Marion J, Bharuca S, et al. The treatment of severe ulcerative and Crohn’s colitis. A critical analysis of the defined trials. J Clin Gastroenterol 1995; 18: 242-6.

  20. Jarnerot G, Rolny P, Saulbergh-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985; 89: 1005-13.

  21. Meyers S, Sachar DB, Goldberg JD, et al. Corticotropin vs hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology 1983; 85: 351-7.

  22. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.

  23. Van Assche G, D’Haens G, Noman M, et al. Randomized double-blind comparison of 4 mg/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis. Gastroenterology 2002; 122: A668.

  24. Sternthal M, George J, Kornbluth A, et al. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996: A1019.

  25. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporine in ulcerative colitis: A 5-year experience. Am J Gastroenterol 1999; 94: 1587-92.

  26. Yoon C, Kornbluth A, George J, et al. Is cyclosporine as effective in chronic ulcerative colitis as in severe ulcerative colitis? Gastroenterology 1998; 114: G4586.

  27. Andreoli A, Falasco G, Mangiaropti R, et al. Efficacy of long-term oral 6-mercaptopurine therapy in maintaining remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Gastroenterology 1999; 116: G2883.

  28. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporine for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44: 1436-40.

  29. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-7.

  30. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-56.

  31. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-62.

  32. Skelly MM, Logan RF, Jenkins D, Mahida YR, Hawkey CJ. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002; 8: 93-7.

  33. Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000; 95:1201-7.

  34. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.

  35. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 677-92.

  36. Sands BE, Anderson FH, Bernstein CN, Che WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-85.

  37. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601-8.

  38. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.

  39. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.

  40. Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn’s disease. N Engl J Med 2003; 348: 601-8.

  41. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84.

  42. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, et al. Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14.

  43. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9.

  44. García-Planella E, Doménech E, Esteve-Comas M, Bernal I, Cabré E, Boix J, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn’s disease treated with chimeric monoclonal anti-TNF alpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 1-4.

  45. Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stokholm County. Gut 2004; 53: 849-53.

  46. Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn’s disease. Gastroenterology 1999; 117: 1433-7.

  47. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24.

  48. Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn’s disease: optimize not immunize. Gastroenterology 2003; 124: 1140-5.

  49. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8.

  50. Ruf G. Surgical therapy of complicated inflammatory bowel disease. Schweiz Rundsch Med Prax 2005; 94(43): 1681-5.

  51. Siegmund B, Zeitz M. Ulcerative colitis? Guidelines 2004. Schweiz Rundsch Med Prax 2005; 94(41): 1599-604.

  52. Almogy G, Sachar DB, Bodian CA, Greenstein AJ. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. Arch Surg 2001; 136(12): 1396-400.

  53. Tsujikawa T, Andoh A, Sakaki M, Ishizuka I, Araki Y, Koyama S, Fujiyama Y. Operative indications for patients with refractory or severe ulcerative colitis. Hepatogastroenterology 2005; 52(65): 1470-3.

  54. Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: systematic review. Gastroenterol-Hepatol 2005; 28(10): 607-14.

  55. Sholmerich J. Complications of chronic inflammatory bowel disorders: treatment. Schweiz Rundsch Med Prax 2005; 94(43): 1671-9.

  56. Berg DF, Bahadursingh MA, Kaminski LD, Longo EW. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 2002; 184: 45-51.

  57. Caprilli R, Vernia P, Colaneri O, Frieri G. Risk factors in toxic megacolon. Dig Dis Sci 1980; 25(11): 817-822.

  58. Hartong WA, Arvanitakis C, Skibba RM, Klotz AP. Treatment of toxic megacolon a comparative review of 29 patients. Dig Dis Sci 1977; 22(3): 195-200.

  59. Gonzalez QH, Lopez F, Muro LJ, Tapia H, Vergara O, Ramos R, Laparoscopic total proctocolectomy with ileal pouch anal anastomosis for ulcerative colitis and familial adenomatous polyposis: inicial experence in Mexico. Surg Endosc 2007; DOI 10.1007/s00464-007-9523-2.

  60. Mahadevan U, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 124: 1638-50.

  61. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis following ileal pouch-anal anastomosis: A pouchitis disease activity index. Mayo Clin Proc 1994; 69: 409-15.

  62. Shen B, Achkar JP, Lashner B, et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001; 121: 261-7.

  63. Shen B, Shermock KB, Fazio VW, et al. A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastamosis. Am J Gastroenterol 2003; 98: 2460-7.

  64. Hurst RD, Molinari M, Chung TP, et al. Prospective study of incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131: 497-502.

  65. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38: 234-9.

  66. Subramani K, Harpaz N, Billotta J, et al. Refractory pouchitis: Does it reflect underlying Crohn’s disease? Gut 1993; 34: 1539-42.

  67. Shen B, Achkar JP, Lashner BA, et al. Irritable pouch syndrome: A new category of diagnosis for symptomatic patients with ileal pouch-anal anastamosis. Am J Gastroenterol 2002; 97: 972-7.

  68. Sandborn W, McLeod R, Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000.

  69. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-5.

  70. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-6.

  71. Sambuelli A, Boerr L, Negreira S, et al. Budesonide enema in pouchitis-A double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002; 16: 27-34.

  72. Gionchetti P, Rizello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A randomized placebo-controlled, double-blind trial. Gastroenterology 2000; 119: 305-9.

  73. Gionchetti P, Rizello F, Venturi A, et al. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind placebo controlled trial. Gastroenterology 2003; 124.

  74. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in ulcerative and left-sided ulcerative colitis. Factors determining risk. Gastroenterology 1979; 77: 290-4.

  75. Sugita A, Sachar DB, Bodian C, et al. Colorectal cancer in ulcerative colitis: Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 1991; 32: 167-9.

  76. Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology 1988; 94: 870-7.

  77. Sachar DB. Cancer risk in inflammatory bowel disease: Myths and metaphors. In: Riddel RH (ed.). Dysplasia and cancer in colitis. New York: Elsevier; 1991, p. 5-9.

  78. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001; 48: 526-35.

  79. Greenstein AJ, Sachar DB, Pucillo A, et al. Cancer in universal and left-sided ulcerative colitis. Clinical and pathological features. Mt Sinai J Med 1979; 46: 25-32.

  80. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis. A cohort study of primary referrals from three centers. Gut 1988; 29: 206-17.

  81. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1999; 94: 1643-9.

  82. Broome U, Lofberg R, Veress B, et al. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.

  83. Nuako KW, Ahlquist DA, Sandborn WJ, et al. Primary sclerosing cholangitis and colorectal carcinoma in patients with chronic ulcerative colitis, a case-control study. Cancer 1998; 82: 822-6.

  84. Loftus E, Sandborn WJ, Tremaine WJ, et al. Cumulative risk factors associated with colorectal neoplasia in 184 patients with primary sclerosing cholangitis with and without ulcerative colitis. Gastroenterology 1996; 110: 432-40.

  85. Pardi DS, Loftus EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93.

  86. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor on colorectal cancer in IBD. Gastroenterology 2001; 120: 1356-62.

  87. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention: A case control study. Aliment Pharmacol Ther 2000; 14: 145-53.

  88. Ullman T, Croog V, Harpaz N, et al. Preventing neoplasia progression in ulcerative colitis: Role of mesalamine (abstract). Gastroenterology 2003; 124: A242.

  89. Greenstein AJ, Slater G, Heimann TM, et al. Comparison of multiple synchronous colorectal cancers in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg 1986; 203: 123-8.

  90. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-44.

  91. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994; 107: 1196-9.

  92. Bernstein CN. Cancer surveillance in inflammatory bowel disease. Curr Gastroenterol Rep 1999: 496-504.

  93. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989; 10: 1536-41.

  94. Eaden JA, Abrams K, Mayberry JS. The risk of colorectal cancer in ulcerative colitis: A meta analysis. Gut 2001; 48: 526-35.

  95. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989; 20: 1008-14.

  96. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colorectal cancer in ulcerative colitis. Gastroenterology 1985; 89: 1342.

  97. Nugent FW, Haggit RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991; 100: 1241-8.

  98. Blackstone M, Riddell RW, Rogers BHG, et al. Dysplasia associated lesion or mass (DALM) detected by colonoscopy in longstanding ulcerative colitis: An indication for colectomy. Gastroenterology 1981; 80: 366-74.

  99. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992; 33: 938-41.

  100. Reiser JR, Waye JD, Janowitz HD, et al. Adenocarcinoma in strictures of ulcerative colitis without antecedent dysplasia by colonoscopy. Am J Gastroenterol 1994; 89: 119-22.

  101. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-4.

  102. Woolrich AJ, DaSilva MD, Korelitz BI. Surveillance in the routine management of ulcerative colitis: The predictive value of low grade dysplasia. Gastroenterology 1992; 103: 431-8.

  103. Ullman TA, Loftus EV, Kakar S, et al. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002; 97: 922-7.

  104. Ullman TA, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125: 1311-9.

  105. Niraj J, Kornbluth A, Croog V, et al. The fate of indefinite dysplasia in ulcerative colitis (abstract). Gastroenterology 2003; 124: A649.




2020     |     www.medigraphic.com